25 results on '"Papadimitrakopoulou, V.A."'
Search Results
2. Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer
3. PD01.06 CANOPY-2: Phase 3 Study of Canakinumab Plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC
4. CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
5. Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
6. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
7. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
8. IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
9. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
10. Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
11. 1587TiP - CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
12. Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
13. Rociletinib-associated cataracts in EGFR-mutant NSCLC
14. Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
15. LBA54 - IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
16. LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
17. LBA49 - Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
18. 1509TiP - Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
19. 439P - Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
20. LBA49 - Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
21. AURA3 Design: a Randomised, Phase III Study of Azd9291 Versus Second-Line Chemotherapy for Patients (PTS) with Egfr-Tki-Resistant (T790M) Advanced Non-Small Cell Lung Cancer
22. LBA46_PR - Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
23. 1294TiP - Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
24. 1239P - Rociletinib-associated cataracts in EGFR-mutant NSCLC
25. Phase III trial of amifostine with chemoradiation for inoperable non-small cell lung cancer (NSCLC): does amifostine protect cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.